Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated Review - PubMed
5 hours ago
- #Minimally invasive surgery
- #Non-small cell lung cancer
- #Oncological outcomes
- Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers, with surgical resection as the gold-standard treatment.
- Minimally invasive surgery (MIS), including VATS and RATS, aims to reduce perioperative morbidity without compromising oncological efficacy.
- VATS shows comparable or superior oncological outcomes to open surgery, especially in early-stage NSCLC.
- RATS demonstrates efficacy comparable to open surgery, even in advanced stages or complex resections, based mainly on retrospective studies.
- VATS and RATS have similar overall survival rates, with some data suggesting a potential disease-free survival advantage for RATS.
- MIS is safe and effective for resectable NSCLC, but further randomized studies are needed to clarify long-term benefits of each technique.